BBT improves glucose homeostasis by ameliorating β-cell dysfunction in type 2 diabetic mice

Area of Science:

• Endocrinology
• Pharmacology
• Cell Biology

Background:

• Type 2 diabetes is characterized by impaired glucose-stimulated insulin secretion (GSIS) and pancreatic beta-cell death.
• Restoring beta-cell function is a key therapeutic strategy for managing type 2 diabetes.

Purpose of the Study:

• To investigate the effects of the small molecule N-(2-benzoylphenyl)-5-bromo-2-thiophenecarboxamide (BBT) on pancreatic beta-cell function.
• To determine BBT's efficacy in potentiating GSIS and protecting beta-cells from apoptosis.

Main Methods:

• BBT was tested for its ability to enhance GSIS and protect beta-cells from cytokine- or streptozotocin (STZ)-induced cell death.
• Signaling pathways including cAMP/PKA and Ca(2+) channels were analyzed.
• BBT's effects were evaluated in a mouse model of type 2 diabetes (STZ/HFD).

Main Results:

• BBT demonstrated efficacy in potentiating GSIS and protecting beta-cells.
• The cAMP/PKA and L-type Ca(2+) channel/CaMK2 pathways were implicated in BBT's GSIS-enhancing effects, while cAMP/PKA was crucial for its protective action.
• In STZ/HFD mice, BBT restored beta-cell function, increased insulin levels, and reduced beta-cell loss.

Conclusions:

• BBT effectively improves beta-cell function by enhancing GSIS and preventing cell death.
• BBT treatment in a type 2 diabetes mouse model led to reduced blood glucose, HbA1c, and improved glucose tolerance.
• BBT shows significant potential as an anti-hyperglycemic agent for type 2 diabetes therapy.